Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | GOT1 | P17174 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2724218 | 0.87 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL29365992 | 0.79 | GOT1 (0.62) | ALDH1A1CYP1A2GOT1SMN1; SMN2NPC1 | |
| SCHEMBL345211 | 0.79 | GOT1 (0.62) | ALDH1A1CYP1A2GOT1SMN1; SMN2NPC1 | |
| SCHEMBL1688224 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CYP1A2CYP2C19GOT1SMN1; SMN2 | |
| SCHEMBL15158687 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CYP1A2CYP2C19GOT1SMN1; SMN2 | |
| SCHEMBL6939703 | 0.79 | MAPT (0.47) | ALDH1A1CYP1A2CYP2C19GOT1SMN1; SMN2 | |
| SCHEMBL3393453 | 0.77 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP2C19GOT1RAB9A | |
| SCHEMBL12215453 | 0.77 | ALDH1A1 (0.78) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL27758703 | 0.77 | GOT1 (0.60) | ALDH1A1CYP1A2GOT1SMN1; SMN2NPC1 | |
| SCHEMBL16295195 | 0.76 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-7705146-B2 | Hepatitis C inhibitor peptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-27 | — | — | US | disclosed |
| EP-1058681-B1 | NOVEL ALLYLTHIOPYRIDAZINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | SEOUL PHARM CO LTD (KR) | 2003-05-07 | — | — | EP | disclosed |
| EP-1058681-A1 | NOVEL ALLYLTHIOPYRIDAZINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | Seoul Pharm. Co., Ltd. (KR) | 2000-12-13 | — | — | EP | disclosed |
| US-5942511-A | PROTECTION OF HUMAN TISSUE FROM RADIATION | Kwon, Soon Kyoung (KR) | 1999-08-24 | — | — | US | disclosed |
| WO-1999036407-A1 | NOVEL ALLYLTHIOPYRIDAZINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | SEOUL PHARM. CO., LTD. (KR) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | ALDH1A1 3399/4885CYP1A2 2856/4885CYP2C19 3390/4885 |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | ALDH1A1 3072/4885CYP1A2 2837/4885CYP2C19 3450/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | ALDH1A1 3218/4885CYP1A2 1794/4885CYP2C19 2333/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | ALDH1A1 3127/4885CYP1A2 1813/4885CYP2C19 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.